12 Best Healthcare Stocks Under $50 to Invest In

Page 7 of 11

5. Roivant Sciences Ltd. (NASDAQ:ROIV)

Number of Hedge Fund Holders: 54

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a bullish outlook on Roivant Sciences Ltd. (NASDAQ:ROIV) on February 6, revising the price target on the stock to $38 from $28 and maintaining a Buy rating. The rating update came the same day Roivant Sciences Ltd. (NASDAQ:ROIV) announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for Q3 ended December 31, 2025.

Roivant Sciences Ltd. (NASDAQ:ROIV) reported that brepocitinib 45 mg considerably improved cutaneous sarcoidosis disease activity and exhibited rapid, deep, and sustained improvements across all other efficacy endpoints measured with a consistent safety profile. Management further stated that an NDA was submitted to the FDA for brepocitinib in dermatomyositis (DM), with topline data from Phase 3 studies in non-infectious uveitis (NIU) anticipated in H2 of calendar year 2026. Roivant Sciences Ltd. (NASDAQ:ROIV) is continually exploring other indications for brepocitinib.

In addition, the company reported $4.5 billion in consolidated cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2025, supporting cash runway into profitability.

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company that develops transformative medicines. Its product portfolio comprises Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. Its product candidates extend across various therapeutic areas, including oncology, immunology, dermatology, and hematology.

Page 7 of 11